SFA Therapeutics
Regulating the immune system to block cancer & autoimmune diseases
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
SFA Therapeutics is creating therapeutically-tailored oral drugs that regulate the immune system; with a focus on autoimmune diseases and cancers that originate from chronic inflammation. There are over 300 million patients who suffer from autoimmune diseases. Our treatment is designed to block the root cause of many of these chronic inflammatory diseases, with safe oral drugs. We have strong clinical data from a phase 1b clinical trial in psoriasis, and human data in pancreatic cancer, uveitis and NASH. we have a total of 9 drugs in our pipeline and 15 patents. SFA Therapeutics is a Y Combinator company (Summer 2021). YC-listed status: Active.
- Website
- sfatherapeutics.com
- Location
- Philadelphia, PA, USA
- Added via
- web
- Ownership
- unclaimed
Where to go
Products
- SFA-002 — Oral deuterated short-chain fatty acid that resets immunity through the gut-immune axis to treat plaque psoriasis and autoimmune diseases. · Other
Links
- Y Combinator profileycombinator